CAS: 115-33-3; (2-Oxoindoline-3,3-Diyl)Bis(4,1-Phenylene) Diacetate

上下游产品

CAS号125-13-3 酚丁 | CAS号91-56-5 靛红 | CAS号122-79-2 乙酸苯酯 | CAS号108-24-7 乙酸酐 | CAS号64-19-7 冰醋酸 | CAS号75-36-5 乙酰氯 | CAS号39033-45-9 AKOS BBS-00005529

📜3,3-二(4-羟基苯基)-2(3H)-吲哚酮置于吡啶,苯甲酰氯,溶剂黄146体系中,化学反应生成双醋酚丁
参考文献:De555813
标题:De555813

专利信息

专利号:US-2007299102-A1
优先权日:2004-04-08
标题:Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
发明人：FELDING JAKOB; PEDERSEN HANS C; KROG-JENSEN CHRISTIAN; PRAESTEGAARD MORTEN; BUTCHER STEVEN P; LINDE VIGGO; COULTER THOMAS S; MONTALBETTI CHRISTIAN; UDDIN MOHAMMED; REIGNIER SERGE
权利人:TOPOTARGET AS
摘要:The present invention relates to substituted 3,3-diphenyl-1,3-dihydro-indol-2-one compounds, and the use of such compounds for the preparation of a medicament for the treatment of cancer in a mammal. It is postulated that treatment of cancers is achieved in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth. Examples of such cancers are breast cancer, renal cancer, multiple myeloma, leukemia, glia blastoma, rhabdomyosarcoma, prostate, soft tissue sarcoma, colorectal sarcoma, gastric carcinoma, head and neck squamous cell carcinoma, uterine, cervical, melanoma, lymphoma, and pancreatic cancer. A particular subclass of compounds are represented by the formula (II) n n nwherein at least one of X 1 and X 2 is a heteroatom substituent, e.g. 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one.

专利号:US-2005053587-A1
优先权日:2001-09-20
标题 :Cultured stromal cells and uses thereof
发明人：GALIPEAU JACQUES; ABDULAZIZ AL-KHALDI; LACHAPELLE KEVIN; ELIOPOULOS NICOLETTA; STAGG JOHN
摘要:The present invention relates to genetically-engineered bone marrow stromal cells and method of preparation thereof for ex vivo delivery of protein and peptides of interest into human or animals. The method includes forming a bone marrow stromal cell expression system in vitro and administering the expression system to a human or animal recipient. The invention relates also to implants colonized by bone marrow stromal cells. In accordance with the invention, the implants comprise a matrix which can be composed of a large variety of biocompatible and biodegradable products, and stromal cells which are integrated into the matrix as such or under genetically-engineered forms. Genetically-engineered bone marrow stromal cells or cell colonized implant are also useful for tissue repair and tissue synthesis, as for angiogenesis.